On Oct 16, major Wall Street analysts update their ratings for $Johnson & Johnson (JNJ.US)$, with price targets ranging from $166 to $215.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $169 to $175.
J.P. Morgan analyst Chris Schott maintains with a hold rating, and maintains the target price at $185.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $180 to $185.
Wells Fargo analyst Larry Biegelsen maintains with a hold rating, and adjusts the target price from $163 to $166.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $185.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Following a Q3 report that matched general expectations, with the Pharmaceuticals segment outperforming and the MedTech segment underperforming, it was noted that adjustments to estimates were slightly modified. The 2025 outlook commentary was also reported to align with prior expectations.
Following Johnson & Johnson's quarterly report, the company's positioning has been reinforced by the progression of the talc litigation settlement proposal, multiple acquisitions in the medical technology field, and 'level-set 2025 commentary.'
Johnson & Johnson's third-quarter earnings surpassed expectations, with a notable 5.6% growth excluding Covid-related sales, primarily fueled by Innovative Medicine's performance. Despite MedTech's lag, which can be attributed to usual seasonal patterns and challenges in the Asia Pacific region, the company is recognized for making significant operational strides. The focus on executing its pipeline is starting to manifest positively.
The anticipated sales growth for 2024 suggests a decrease in growth during Q4; however, management commentary pertaining to 2025 appears promising for potential EPS growth. Additionally, there is an indication that significant headway has been achieved in addressing the talc litigation.
Johnson & Johnson's recent performance exceeded expectations, particularly within its Pharmaceutical division, which contributed to surpassing third-quarter sales and EPS projections. The company's early outlook for 2025 indicates that its business fundamentals remain consistent. However, when considering the company's valuation, it seems that the shares are appropriately priced.
Here are the latest investment ratings and price targets for $Johnson & Johnson (JNJ.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
